BMC CancerCancer BiologyPeer-reviewed journal article
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell Engaging antibodies) for cellular immunotherapy
M. Kujawski, L. Li, S. Bhatacharya, P. Wong, W.-H. Lee, L. (Obrien) Williams, H. Li, J. Cheah, K. Poku, N. Bowles, N. Vaidehi, P. Yazaki, J. E. Shively
Abstract
Bispecific T-cell engaging antibodies (BiTES), comprising dual anti-CD3 and anti-tumor antigen scFv fragments, are important therapeutic agents for the treatment of cancer. The dual scFv construct for BiTES requires proper protein folding while their small molecular size leads to rapid kidney clearance. Here we show that an intact (150 kDa) anti-tumor antigen antibody to CEA was joined in high yield (ca. 30%) to intact (150 kDa) anti-murine and anti-human CD3 antibodies using hinge region specific Click chemistry to form dual-specific, bivalent BiTES (db BiTES, 300 kDa). The interlocked hinge regions are compatible with a structural model that fits the electron micrographs of the 300 kDa particles. Compared to intact anti-CEA antibody, dbBiTES maintain high in vivo tumor targeting as demonstrated by PET imaging, and redirect dbBiTE coated T-cells (1 microgram/10 million cells) to kill CEA+ target cells both in vitro, and in vivo in CEA transgenic mice.
- organism: mouse
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Enhancing the anti-tumor efficacy of Bispecific T cell engagers via cell surface glycocalyx editing
- A Simplified Function-First Method for the Discovery and Optimization of Bispecific Immune Engaging Antibodies
S. McComb, A. Shepherd, … R. Weeratna·bioRxiv·Aug 17, 2022
- Locally secreted BiTEs complement CAR T cells by enhancing solid tumor killing
Y. Yin, J. Rodriguez, … D. M. O'Rourke·bioRxiv·Jun 8, 2021
- Bivalent bispecific CD28 antibodies reinforce T-cell responsiveness and revert anergy/quiescence in patients treated with bispecific CD3 antibodies
Latifa Zekri, Natalie Köhler, … Helmut Rainer Salih·bioRxiv·Sep 20, 2026
- Overcoming Tumor Heterogeneity by Ex Vivo Arming of T Cells Using Multiple Bispecific Antibodies
N.-K. Cheung, J. A. Park·bioRxiv·Aug 31, 2021
- T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T-cells
Matthias Obenaus, Clara L. Poupault, … K. Christopher García·bioRxiv·Jan 27, 2026